Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P21912
UPID:
SDHB_HUMAN
Alternative names:
Iron-sulfur subunit of complex II
Alternative UPACC:
P21912; B2R545; Q0QEY7; Q9NQ12
Background:
The Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial, also known as the Iron-sulfur subunit of complex II, plays a pivotal role in cellular energy production. This protein is an integral component of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), facilitating the transfer of electrons from succinate to ubiquinone (coenzyme Q).
Therapeutic significance:
Mutations in this protein are linked to several diseases, including Pheochromocytoma, Paragangliomas 4, Paraganglioma and gastric stromal sarcoma, and Mitochondrial complex II deficiency, nuclear type 4. These associations underscore the protein's potential as a target for therapeutic intervention in these conditions.